Page last updated: 2024-11-05

thalidomide and Parotid Diseases

thalidomide has been researched along with Parotid Diseases in 1 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Parotid Diseases: Diseases involving the PAROTID GLAND.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bensaid, P1
Machet, L1
Vaillant, L1
Machet, MC1
Scotto, B1
Lorette, G1

Reviews

1 review available for thalidomide and Parotid Diseases

ArticleYear
[Langerhans-cell histiocytosis in the adult: regressive parotid involvement following thalidomide therapy].
    Annales de dermatologie et de venereologie, 1992, Volume: 119, Issue:4

    Topics: Adult; Female; Histiocytosis, Langerhans-Cell; Humans; Intertrigo; Parotid Diseases; Pregnancy; Preg

1992